BridgeBio Pharma (BBIO) Other Gross PP&E Adjustments (2019 - 2025)
BridgeBio Pharma's Other Gross PP&E Adjustments history spans 7 years, with the latest figure at -$28.8 million for Q4 2025.
- For Q4 2025, Other Gross PP&E Adjustments fell 7.05% year-over-year to -$28.8 million; the TTM value through Dec 2025 reached -$28.8 million, down 7.05%, while the annual FY2025 figure was -$28.8 million, 7.05% down from the prior year.
- Other Gross PP&E Adjustments for Q4 2025 was -$28.8 million at BridgeBio Pharma, down from -$7.3 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$7.0 million in Q3 2024 and bottomed at -$29.5 million in Q1 2024.
- The 5-year median for Other Gross PP&E Adjustments is -$14.3 million (2022), against an average of -$16.2 million.
- The largest annual shift saw Other Gross PP&E Adjustments tumbled 102.5% in 2024 before it skyrocketed 68.88% in 2025.
- A 5-year view of Other Gross PP&E Adjustments shows it stood at -$26.1 million in 2021, then surged by 52.3% to -$12.5 million in 2022, then decreased by 23.83% to -$15.4 million in 2023, then crashed by 74.08% to -$26.9 million in 2024, then decreased by 7.05% to -$28.8 million in 2025.
- Per Business Quant, the three most recent readings for BBIO's Other Gross PP&E Adjustments are -$28.8 million (Q4 2025), -$7.3 million (Q3 2025), and -$13.3 million (Q2 2025).